These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35452792)

  • 1. Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery.
    Wang W; Ouyang D
    Drug Discov Today; 2022 Aug; 27(8):2100-2120. PubMed ID: 35452792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model.
    Tang C; Ou-Yang CX; Chen WJ; Zou C; Huang J; Cui C; Yang S; Guo C; Yang XY; Lin Y; Pei Q; Yang GP
    Eur J Pharm Sci; 2022 Jan; 168():106055. PubMed ID: 34742834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
    Yang Y; Zhang X
    Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modelling to guide drug delivery in older people.
    Chetty M; Johnson TN; Polak S; Salem F; Doki K; Rostami-Hodjegan A
    Adv Drug Deliv Rev; 2018 Oct; 135():85-96. PubMed ID: 30189273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches.
    Kato T; Nakagawa H; Mikkaichi T; Miyano T; Matsumoto Y; Ando S
    Eur J Pharm Biopharm; 2020 Jun; 151():45-52. PubMed ID: 32298756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute.
    Smits A; De Cock P; Vermeulen A; Allegaert K
    Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):25-34. PubMed ID: 30554542
    [No Abstract]   [Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.
    Franchetti Y; Nolin TD
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S36-S51. PubMed ID: 33205428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.